Vir Biotechnology (VIR.US) stock soars more than 14.0% after the drugmaker announced that recent data regarding its Covid-19 antibody therapy, which was developed in cooperation with GlaxoSmithKline (GSK.UK), showed positive effects against the omicron strain.
Vir Biotechnology (VIR.US) stock has been trading in a sideways move with some downside recently. However following positive news regarding the vaccine, stock launched today's session with a bullish price gap, nevertheless buyers failed to break above the upper limit of the consolidation zone around $54.15. As long as the price sits below, another downward impulse towards support at $34.30 may be launched. On the other hand, if bulls will manage to break above the aforementioned resistance, then upward move may accelerate towards $67.50, where March highs are located. Source: xStation5
Stronger payrolls for September won’t disrupt risk recovery
Palo Alto - after Earnings
Chart of the day: US100 (20.11.2025)
Nvidia's perfect earnings
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
